Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALK-Flex SQ
- Development stage
- Unknown
- Lead developer
- ALK Abelló
- Modality
- Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
ALK-Flex SQ is a subcutaneous immunotherapy product developed for the treatment of grass pollen-induced allergic rhinoconjunctivitis. It is designed to provide equivalent pharmacodynamic efficacy and tolerability across different updosing schedules. The drug contains allergen extracts targeting grass pollen, specifically Phleum pratense (timothy grass), and aims to modulate the immune system's response to allergens, thereby reducing symptoms in patients with a history of insufficient relief from symptomatic medication[1]. The mechanism of action involves repeated exposure to allergen extracts via subcutaneous injection, which helps "re-educate" the immune system and reduce allergic reactions over time[6].
- Brand names
- ALK-Flex SQ
- Other names
- ALK-Flex SQ
02
Targets
T-cell receptor recognizing Phleum pratense-derived peptides presented by HLA class IITimothy grass-specific IgE (Timothy grass-specific immunoglobulin E)B-cell receptor specific for Phleum pratense allergens
Beyond the preview
Go deeper on ALK-Flex SQ.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALK-Flex SQ.